 NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Childrens Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazias investigational new drug, GDC-0084 in diffuse intrinsic pontine glioma DIPG and other diffuse midline gliomas, which represent a group of childhood brain cancers with high unmet need. Dr. Christopher Tinkle, co-Lead Investigator on the study, commented, to date, thirteen patients have received GDC-0084 in our study. 